Possible increase in serum FABP4 level despite adiposity reduction by canagliflozin, an SGLT2 inhibitor

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Furuhashi, Masato ^a   Matsumoto, Megumi ^a   Hiramitsu, Shinya ^b   Omori, Akina ^a   Tanaka, Marenao ^a   Moniwa, Norihito ^a   Yoshida, Hideaki ^a   Ishii, Junnichi ^c   Miura, Tetsuji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Hiramitsu Clinic   (Japan)

^c FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CANAGLIFLOZIN; CHOLESTEROL; CREATININE; CYSTATIN C; FATTY ACID BINDING PROTEIN 4; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITROGEN; NORADRENALIN; TRIACYLGLYCEROL; UREA; URIC ACID; ANTIDIABETIC AGENT; FABP4 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DISEASE ASSOCIATION; DRUG ACTIVITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; KIDNEY FAILURE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORADRENALIN BLOOD LEVEL; OBESITY; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL; ADIPOCYTE; AGED; BLOOD; DIABETES MELLITUS, TYPE 2; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ADIPOCYTES; AGED; BLOOD GLUCOSE; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; FATTY ACID-BINDING PROTEINS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; NOREPINEPHRINE; TREATMENT OUTCOME;

EID: 84964950969     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0154482     Document Type: Article

References (37)

1. Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 2008; 7(6):489-503. Epub 2008/05/31. doi: 10.1038/nrd2589 MID: 18511927.
2. Furuhashi M, Ishimura S, Ota H, Miura T. Lipid chaperones and metabolic inflammation. Int J Inflam. 2011; 2011:642612. Epub 2011/11/29. doi: 10.4061/2011/642612 PMID: 22121495.
3. Furuhashi M, Saitoh S, Shimamoto K, Miura T. Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases. Clin Med Insights Cardiol. 2014; 8(Suppl 3):23-33. doi: 10.4137/CMC.S17067 PMID: 25674026.
4. Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science. 1996; 274(5291):1377-9. Epub 1996/11/22. PMID: 8910278.
5. Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, et al. Lack of macrophage fattyacid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med. 2001; 7(6):699-705. Epub 2001/06/01. doi: 10.1038/89076 PMID: 11385507.
6. Furuhashi M, Fucho R, Gorgun CZ, Tuncman G, Cao H, Hotamisligil GS. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest. 2008; 118(7):2640-50. Epub 2008/06/14. doi: 10.1172/JCI34750 MID: 18551191.
7. Furuhashi M, Tuncman G, Gorgun CZ, Makowski L, Atsumi G, Vaillancourt E, et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature. 2007; 447(7147):959-65. pub 2007/06/08. doi: 10.1038/nature05844 PMID: 17554340.
8. Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem. 2006; 52(3):405-13. pub 2006/01/21. doi: 10.1373/clinchem.2005.062463 PMID: 16423904.
9. Cao H, Sekiya M, Ertunc ME, Burak MF, Mayers JR, White A, et al. Adipocyte lipid chaperone AP2 is a secreted adipokine regulating hepatic glucose production. Cell Metab. 2013; 17(5):768-78. Epub 2013/ 05/15. doi: 10.1016/j.cmet.2013.04.012 PMID: 23663740.
10. Mita T, Furuhashi M, Hiramitsu S, Ishii J, Hoshina K, Ishimura S, et al. FABP4 is secreted from adipocytes by adenyl cyclase-PKA- and guanylyl cyclase-PKG-dependent lipolytic mechanisms. Obesity (Silver Spring). 2015; 23(2):359-67. doi: 10.1002/oby.20954 PMID: 25521833.
11. Ertunc ME, Sikkeland J, Fenaroli F, Griffiths G, Daniels MP, Cao H, et al. Secretion of fatty acid binding protein aP2 from adipocytes through a nonclassical pathway in response to adipocyte lipase activity. J Lipid Res. 2015; 56(2):423-34. doi: 10.1194/jlr.M055798 PMID: 25535287.
12. Furuhashi M, Fuseya T, Murata M, Hoshina K, Ishimura S, Mita T, et al. Local Production of Fatty Acid-Binding Protein 4 in Epicardial/Perivascular Fat and Macrophages Is Linked to Coronary Atherosclerosis. Arterioscler Thromb Vasc Biol. 2016. doi: 10.1161/ATVBAHA.116.307225 PMID: 27013610.
13. Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH, et al. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation. 2007; 115(12):1537-43. Epub 2007/03/29. doi: 10.1161/CIRCULATIONAHA.106.647503 PMID: 17389279.
14. Tso AW, Xu A, Sham PC, Wat NM, Wang Y, Fong CH, et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care. 2007; 30(10):2667-72. Epub 2007/07/11. doi: 10.2337/dc07-0413 PMID: 17620449.
15. Ishimura S, Furuhashi M, Watanabe Y, Hoshina K, Fuseya T, Mita T, et al. Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population. PLoS ONE. 2013; 8 (11):e81318. Epub 2013/11/28. doi: 10.1371/journal.pone.0081318 PMID: 24278421.
16. Ota H, Furuhashi M, Ishimura S, Koyama M, Okazaki Y, Mita T, et al. Elevation of fatty acid-binding protein is predisposed by family history of hypertension and contributes to blood pressure elevation. Am J Hypertens. 2012; 25(10):1124-30. Epub 2012/06/22. doi: 10.1038/ajh.2012.88 PMID: 22717543.
17. Fuseya T, Furuhashi M, Yuda S, Muranaka A, Kawamukai M, Mita T, et al. Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population. Cardiovasc Diabetol. 2014; 13(1):126. doi: 10.1186/s12933-014-0126-7 PMID: 25142635.
18. Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, et al. Plasma fatty acid-binding protein increases with renal dysfunction in type 2 diabetic patients without microalbuminuria. Clin Chem. 2008; 54(1):181-7. doi: 10.1373/clinchem.2007.094672 PMID: 18024526.
19. Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, et al. Plasma fatty acid binding protein is associated with atherogenic dyslipidemia in diabetes. J Lipid Res. 2008; 49(8):1746-51. doi: 10.1194/jlr.M800102-JLR200 PMID: 18421072.
20. Yeung DC, Xu A, Cheung CW, Wat NM, Yau MH, Fong CH, et al. Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2007; 27(8):1796-802. Epub 2007/05/19. doi: 10.1161/ATVBAHA.107.146274 PMID: 17510463.
21. Furuhashi M, Ishimura S, Ota H, Hayashi M, Nishitani T, Tanaka M, et al. Serum fatty acid-binding protein is a predictor of cardiovascular events in end-stage renal disease. PLoS ONE. 2011; 6(11): e27356. Epub 2011/11/22. doi: 10.1371/journal.pone.0027356 PMID: 22102888.
22. von Eynatten M, Breitling LP, Roos M, Baumann M, Rothenbacher D, Brenner H. Circulating adipocyte fatty acid-binding protein levels and cardiovascular morbidity and mortality in patients with coronary heart disease: a 10-year prospective study. Arterioscler Thromb Vasc Biol. 2012; 32(9):2327-35. Epub 2012/06/09. doi: 10.1161/ATVBAHA.112.248609 PMID: 22679309.
23. Chow WS, Tso AW, Xu A, Yuen MM, Fong CH, Lam TH, et al. Elevated circulating adipocyte-fatty acid binding protein levels predict incident cardiovascular events in a community-based cohort: a 12-year prospective study. J Am Heart Assoc. 2013; 2(1):e004176. doi: 10.1161/JAHA.112.004176 PMID: 23525430.
24. Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, et al. Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis. 2007; 195(1):e150-8. Epub 2007/06/08. doi: 10.1016/j.atherosclerosis.2007.04.045 PMID: 17553506.
25. Furuhashi M, Hiramitsu S, Mita T, Fuseya T, Ishimura S, Omori A, et al. Reduction of serum FABP4 level by sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes mellitus. J Lipid Res. 2015; 56(12):2372-80. doi: 10.1194/jlr.M059469 PMID: 26467280.
26. Rajeev SP, Cuthbertson DJ, Wilding JP. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition. Diabetes Obes Metab. 2016; 18(2):125-34. doi: 10.1111/dom.12578 PMID: 26403227.
27. Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014; 124(2):499-508. doi: 10. 1172/JCI72227 PMID: 24463454.
28. Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014; 124 (2):509-14. doi: 10.1172/JCI70704 PMID: 24463448.
29. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53(6):982-92. Epub 2009/04/03. doi: 10.1053/ j.ajkd.2008.12.034 PMID: 19339088.
30. Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thevenet J, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015; 21(5):512-7. doi: 10.1038/nm.3828 PMID: 25894829.
31. Taylor SI, Blau JE, Rother KI. SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab. 2015; 100(8):2849-52. doi: 10.1210/jc.2015-1884 PMID: 26086329.
32. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22):2117-28. doi: 10.1056/ NEJMoa1504720 PMID: 26378978.
33. Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 iabetes. N Engl J Med. 2016; 374(11):1094. doi: 10.1056/NEJMc1600827 PMID: 26981940.
34. Miyoshi T, Doi M, Hirohata S, Kamikawa S, Usui S, Ogawa H, et al. Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients. Heart Vessels. 2011; 26 (4):408-13. Epub 2010/11/11. doi: 10.1007/s00380-010-0060-x PMID: 21063874.
35. Furuhashi M, Mita T, Moniwa N, Hoshina K, Ishimura S, Fuseya T, et al. Angiotensin II receptor blockers decrease serum concentration of fatty acid-binding protein 4 in patients with hypertension. Hypertens Res. 2015; 38(4):252-9. doi: 10.1038/hr.2015.2 PMID: 25672659.
36. Karpisek M, Stejskal D, Kotolova H, Kollar P, Janoutova G, Ochmanova R, et al. Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia. Eur J Clin Invest. 2007; 37(8):637-42. Epub 2007/07/20. doi: 10.1111/j.1365-2362.2007.01835.x PMID: 17635574.
37. Furuhashi M, Hiramitsu S, Mita T, Omori A, Fuseya T, Ishimura S, et al. Reduction of circulating FABP4 level by treatment with omega-3 fatty acid ethyl esters. Lipids Health Dis. 2016; 15(1):5. doi: 10.1186/ s12944-016-0177-8 PMID: 26754658.